JANX Janux Therapeutics, Inc.

Nasdaq januxrx.com


$ 25.74 $ -0.78 (-2.93 %)    

Wednesday, 22-Oct-2025 12:35:35 EDT
QQQ $ 604.27 $ -6.56 (-1.07 %)
DIA $ 466.96 $ -2.26 (-0.48 %)
SPY $ 667.06 $ -4.86 (-0.72 %)
TLT $ 91.99 $ 0.00 (0 %)
GLD $ 373.69 $ 0.61 (0.16 %)
$ 26.83
$ 26.53
$ 25.69 x 1
$ 25.76 x 11
$ 25.35 - $ 26.53
$ 21.73 - $ 71.71
682,750
na
1.61B
$ 1.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-10-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-initiates-coverage-on-janux-therapeutics-with-overweight-rating-announces-price-target-of-47

Barclays analyst Etzer Darout initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overweight rating and announces ...

 truist-securities-initiates-coverage-on-janux-therapeutics-with-buy-rating-announces-price-target-of-100

Truist Securities analyst Asthika Goonewardene initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and ...

 stifel-reinstates-buy-on-janux-therapeutics-announces-45-price-target

Stifel analyst Bradley Canino reinstates Janux Therapeutics (NASDAQ:JANX) with a Buy and announces $45 price target.

 guggenheim-initiates-coverage-on-janux-therapeutics-with-buy-rating-announces-price-target-of-72

Guggenheim analyst Brad Canino initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and announces Price ...

 piper-sandler-initiates-coverage-on-janux-therapeutics-with-overweight-rating-announces-price-target-of-42

Piper Sandler analyst Kelsey Goodwin initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overweight rating and ann...

Core News & Articles

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel...

 janux-therapeutics-showcases-advancements-in-tractr-tracir-and-arm-platforms-ahead-of-2026-trials-at-rd-day-webcast

PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to furth...

 raymond-james-initiates-coverage-on-janux-therapeutics-with-outperform-rating-announces-price-target-of-65

Raymond James analyst Sean McCutcheon initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating and an...

 janux-therapeutics-q1-eps-038-beats-041-estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(...

 janux-therapeutics-initiates-phase-1b-expansion-studies-in-ongoing-engager-psma-01-trial

Phase 1b expansion study initiated in taxane-naïve mCRPC patientsUpdated data from Phase 1a dose escalation support initiation ...

 hc-wainwright--co-reiterates-buy-on-janux-therapeutics-maintains-70-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX) with a Buy and maintains ...

 scotiabank-maintains-sector-perform-on-janux-therapeutics-lowers-price-target-to-41

Scotiabank analyst George Farmer maintains Janux Therapeutics (NASDAQ:JANX) with a Sector Perform and lowers the price targe...

 janux-therapeutics-q4-2024-gaap-eps-036-beats-047-estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(...

 cantor-fitzgerald-reiterates-overweight-on-janux-therapeutics-maintains-200-price-target

Cantor Fitzgerald analyst Josh Schimmer reiterates Janux Therapeutics (NASDAQ:JANX) with a Overweight and maintains $200 pri...

 soundhound-asana-and-victorias-secret-are-among-top-10-mid-cap-gainers-last-week-dec-2-dec-6-are-the-others-in-your-portfolio

Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecas...

 reported-earlier-janux-therapeutics-prices-350m-public-offering-of-5317460-common-shares-63shares-and-pre-funded-warrants

The Company intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION